MindWalk (HYFT) Q3 2026 earnings review
SaaS Validation Achieved, But Profitability Remains Elusive
MindWalk (formerly ImmunoPrecise) delivered its third consecutive quarter of year-over-year revenue growth, up 52% to $4.16M, driven by a doubling of U.S. revenue. The company hit a major strategic milestone by securing its first annual enterprise contract for the LensAI platform, marking a tangible shift toward recurring software revenue. However, the transition is proving costly. Gross margins compressed from 65% to 59% year-over-year, and operating expenses surged as the company builds out its sales force, pushing Adjusted EBITDA loss wider to $3.06M. While a $14.1M cash pile provides a stable runway, investors will want to see top-line momentum start bridging the gap to profitability.
🐂 Bull Case
Signing the first one-year enterprise contract for LensAI validates the company's pivot from a regional lab service provider to a high-value Bio-Native AI platform. This introduces a recurring revenue stream to a previously project-based business.
U.S. revenue doubled year-over-year to $2.6M, confirming that recent commercial investments and the strategic establishment of Boston/Cambridge operations are successfully capturing demand in the world's premier biotech hub.
🐻 Bear Case
A software-led pivot should structurally increase margins, yet MindWalk's gross margin fell from 65% to 59% YoY. If scaling AI requires heavy discounting or intense human-in-the-loop lab support, the SaaS margin thesis is at risk.
Despite a leaner profile post-EU divestiture, operating expenses continue to climb (S&M up 58% YoY), pushing the quarterly net loss to $3.9M. The $14.1M cash buffer is adequate for now, but aggressive commercial expansion will drain it.
⚖️ Verdict: ⚪
Neutral. Top-line execution and the first enterprise SaaS win are undeniable positives. However, deteriorating gross margins and escalating operating expenses show that the costly reality of pivoting a business model is heavily weighing on the bottom line.
Key Themes
U.S. Penetration and Enterprise SaaS Pivot Accelerating
MindWalk's deliberate focus on the North American market is paying off, with U.S. revenue accelerating 100% year-over-year to $2.6M. More importantly, the company secured its first one-year LensAI platform contract with its largest enterprise AI client. This shift from project-based fee-for-service to contracted, recurring revenue is the core pillar of the company's long-term valuation strategy.
B cell Llama™ Launch Targets Bispecific Bottleneck
The company launched the B cell Llama™ nanobody discovery platform. VHH nanobodies lack a light chain, solving the chain-pairing problems that plague multi-specific antibody development. By combining this in-vivo capability with the LensAI computational platform, MindWalk is directly targeting a bispecific therapeutics market projected to exceed $50 billion by 2030.
Internal Asset Validation Rapidly Advancing
Internal AI-generated programs are showing formidable progress. The GLP-1 program demonstrated in vitro receptor activation relative to semaglutide (a $29B market leader). The Universal Dengue Vaccine program identified a single conserved epitope across all four serotypes using LensAI, successfully completing in vivo immunization studies. If successful in multi-serotype neutralization testing, these assets represent massive out-licensing potential.
Gross Margin Decelerating Despite Software Pivot
A key concern is the reversing trend in profitability. Gross margin decelerated from 65% in 25Q3 to 59% in 26Q3. While management previously noted (in Q1) that large SaaS deals might require initial R&D discounts, investors must monitor whether this is a temporary onboarding cost or a structural reality that LensAI deployments still require heavy, low-margin wet-lab integration.
Persistent Material Weakness in Internal Controls
Management once again reported that disclosure controls and procedures were not effective as of January 31, 2026, due to a material weakness related to insufficient resources for identifying and addressing complex technical accounting issues. Relying heavily on outside consultants to fix fundamental reporting deficiencies is a lingering red flag for institutional investors.
Operating Expenses Outpacing Revenue Gains
While revenue grew by $1.4M YoY, operating expenses (excluding prior year impairments) expanded significantly. Sales and marketing spiked 58% YoY to $1.8M, reflecting commercialization efforts and the hiring of a Chief Business Officer. This indicates that acquiring new enterprise SaaS clients is highly capital intensive.
Other KPIs
Decelerating. Adjusted EBITDA loss widened from $(2.19)M in 25Q3 and $(2.42)M in 26Q2. The expansion in loss is primarily driven by a $0.66M increase in sales and marketing expenses and increased R&D spend to support the LensAI platform.
Stable. The cash position declined slightly from $16.5M in Q2 but remains significantly higher than the $10.7M reported at the end of FY25, largely due to the $14.3M in net proceeds from the Q1 divestiture of European operations.
Accelerating. Up 46.6% from $7.70M in the same period last year, reinforcing that the core underlying biologics discovery and software integration business is capturing steady market share.
Guidance
Reversing. Management explicitly noted that the $14.1M cash on hand is expected to be sufficient to fund operations for at least one year. This is a crucial positive reversal from the FY25 and Q1 FY26 filings, where management warned that cash was insufficient to fund 12 months of operations without additional financing.
Key Questions
Margin Compression Drivers
Gross margins compressed from 65% to 59% year-over-year. How much of this is driven by initial discounting to secure the new enterprise LensAI contract, versus a structural shift in the cost of executing these hybrid software/wet-lab projects?
SaaS Contract Economics
Regarding the first annual enterprise LensAI contract, what is the typical Annual Contract Value (ACV) for these engagements, and how is the revenue being recognized across the quarters?
Asset Financing Timelines
You engaged advisors to design asset-level financing vehicles (likely the Cayman segregated portfolio structure) for GLP-1, Dengue, and Influenza. When do you realistically expect to announce the first external capital injection into one of these specific asset vehicles?
Internal Control Remediation
The material weakness regarding technical accounting resources remains unresolved. Given the new complex structures being evaluated (like asset-level financing), when will permanent in-house resources be sufficient to fully remediate this weakness?